“Indian companies are moving from API manufacturing to Formulations”
BioSpectrum Asia|October 2020
The COVID-19 pandemic has unlocked several opportunities for the life sciences sector in India. And in response to this, the sector has taken the right plunge. KPMG’s new report on ‘Site selection for life sciences in Asia’ reveals the true potential has India possess. In an interview, Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG, India expounds on the key findings of this study and shares insights on key market drivers. Edited excerpts;
Raelene Kambli
“Indian companies are moving from API manufacturing to Formulations”

Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG, India

KPMG has recently released a report on “Site Selection for Life Sciences Companies in Asia”. Can you tell us the key findings?

Asia is one of the fastest-growing markets for the life sciences industry. A huge chunk of demand is met by Asian countries alone. Along with this, there has been significant improvement with respect to domestic industries. This report covers key elements of businesses in these countries and discusses the value chain as well.

This story is from the October 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the October 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Ushering Fourth Industrial Revolution in Telangana
BioSpectrum Asia

Ushering Fourth Industrial Revolution in Telangana

Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).

time-read
6 mins  |
BioSpectrum Asia April 2024
How Indian Biotech Investments are on a Doubling Spree
BioSpectrum Asia

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

time-read
4 mins  |
BioSpectrum Asia April 2024
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
BioSpectrum Asia

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

time-read
5 mins  |
BioSpectrum Asia April 2024
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
BioSpectrum Asia

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

time-read
4 mins  |
BioSpectrum Asia April 2024
Can Test, Treat, Track Beat Malaria?
BioSpectrum Asia

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

time-read
8 mins  |
BioSpectrum Asia April 2024
Engineering CAR T cell sharpshooters
BioSpectrum Asia

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

time-read
6 mins  |
BioSpectrum Asia April 2024
Addressing Challenges in Cell Therapy Manufacturing
BioSpectrum Asia

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

time-read
2 mins  |
BioSpectrum Asia April 2024
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
BioSpectrum Asia

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

time-read
5 mins  |
BioSpectrum Asia April 2024
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
BioSpectrum Asia

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

time-read
10+ mins  |
BioSpectrum Asia April 2024
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024